Targeting Insulin-Like Growth Factor-I in Management of Neurological Disorders

Neurotox Res. 2022 Jun;40(3):874-883. doi: 10.1007/s12640-022-00513-7. Epub 2022 Apr 27.

Abstract

The degradation of neurons marks as the pathological reason for onset of most of the neurological diseases although the functional deficiencies and symptoms may vary. Insulin-like growth factor-I (IGF-I) boosts regeneration of both motor and sensory neurons and thus presents as a potential treatment in management of neurological disorders. IGF-I is a pleiotropic agent which stimulates the survival and outgrowth of neurons accompanied by their motility as well as myelination by glial cells. This hormone has been found to possess neuroprotective properties which is in association with its antioxidant and mitochondrial protection activity. Studying and exploring the signaling pathways which mediate pleotropic responses intracellularly have elucidated significant therapeutic approach in treatment and management of neurological disorders by IGF-I. The current review highlights the role of IGF-I in management of major neurological disorders such as depression, Parkinson's disease, and Alzheimer's disease and also covers the mechanisms involved in the process.

Keywords: Alzheimer’s disease; Depression; Insulin-like growth factor; Neurodegeneration; Parkinson’s disease.

Publication types

  • Review

MeSH terms

  • Alzheimer Disease*
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • Nervous System Diseases* / drug therapy
  • Neurons / metabolism
  • Parkinson Disease* / drug therapy

Substances

  • Insulin-Like Growth Factor I